ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO475

Improvement of Depressive Symptoms and Quality-of-Life in Patients on Home Hemodialysis

Session Information

  • Home Dialysis - 2
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • D'Alessandri-Silva, Cynthia J., Outset Medical, San Jose, California, United States
  • Gunter, Christopher, Outset Medical, San Jose, California, United States
  • Aragon, Michael A., Outset Medical, San Jose, California, United States
  • Henner, David E., Berkshire Health Systems, Pittsfield, Massachusetts, United States
Background

Patients with end-stage renal disease (ESRD) commonly report depressive symptoms (e.g., feeling hopeless, suicidal thoughts), significantly impacting quality-of-life (QOL) and feelings of self-worth (e.g., feeling like a failure, letting your family down). These symptoms can impact a patient’s overall sense of well-being as well as treatment recovery time. The HOME Registry Study (NCT04526301) is a multi-center, prospective, study on patients receiving home hemodialysis (HHD) with the Tablo® Hemodialysis System.

Methods

In this interim analysis of HOME we report results from the Patient Health Questionnaire-9 (PHQ-9), Time-to-Recovery (TTR), and Participant Net Promotor Score (NPS) to quantify the impact of Tablo HHD on participants’ mental health and perceived QOL.

Results

99 subjects were enrolled into the HOME Registry, with mean age of 57, 73% male, 78% non-Hispanic/Latino, and 70% married or in a domestic relationship. PHQ-9 responses from baseline to month-12 are as follows- Q1: no incidence of "feeling down, depressed, or hopeless"- baseline 68%, 12 month 74%; (90% reported this feeling ≤2 times over a 2-week period at 12 months); Q2: no incidence of "feeling bad about yourself-or that you are a failure"- baseline 65%, 12 months 77% (84% reported this feeling ≤2 times over a 2-week period at 12 months). Q3: no incidence of "thoughts that you would be better off dead or hurting yourself"-baseline 89%, 12 months 94%; (7% reporting this feeling ≤2 times over a 2-week period). Over 80% of participants at month-12 reported their HHD making no/some impact on their ability to work, take care of their home and getting along with others.
TTR of <60min trended positively over 12 months of HHD, increasing 5.5%. Mean NPS score for likelihood of recommending HHD with Tablo to other ESKD patients on a point scale from 1 “not likely” to 10 “extremely likely” was 9.2 at month-6 and 9.3 at month-12 visit.

Conclusion

HOME Registry patients on Tablo report improvement in depressive symptoms and low time to recovery out to 12 months. At both 6 and 12 months at home performing self-care, patients are extremely likely to recommend home hemodialysis via Tablo to other patients.